报告期，公司业务规模和盈利能力均实现了较快增长，主要原因如下：1、随着市场对高质量产品的需 求，公司对标进口产品，持续加大科研投入，做到质量全面一致性。得益于公司研发能力和较好的品牌 影响力，客户对公司产品的依赖度较高。报告期，公司主要产品的业务订单一直较为充足，增长势头明 显。2、面临国内市场的竞争压力，公司保持高端制剂业务稳健增长同时，积极开拓国际贸易新市场。 2025年，公司外贸业务继续保持较高增长，与内贸业务同频贡献，实现了整体营业收入规模的较高增 长。3、公司上年度对控股子公司资产组计提了商誉减值3,912.69万元，对当期利润影响较大，本报告期 无计提商誉减值的影响。报告期，预计非经常性损益对公司净利润的影响额约为1,750万元，主要系暂 时闲置资金的理财收益，上年非经常性损益金额为1,826.72万元。 格隆汇1月14日丨山河药辅(300452.SZ)公布，预计2025年归属于上市公司股东的净利润16,500万 元-19,400万元，比上年同期增长38.16%-62.45%，归属于上市公司股东的扣除非经常性损益的净利润 14,700万元-17,500万元，比上年同期增长45.32%-73.00% ...

Core Viewpoint - The article discusses the recent earnings forecasts of A-share companies for 2025, highlighting that while many companies report significant profit increases, the sustainability of these growth figures is questionable due to underlying business conditions and accounting practices [1][3]. Group 1: Earnings Forecasts - 87 A-share companies have disclosed their earnings forecasts for 2025, with 17 companies projecting a year-on-year increase in net profit exceeding 100% [1]. - Notable companies with high profit growth forecasts include: - Zhongke Lanyun: projected net profit increase of 366% to 376% [2]. - Chuanhua Zhili: expected increase of 361.57% due to operational improvements and asset sales [2]. - Kangchen Pharmaceutical: forecasted increase of 315% attributed to reduced impairment losses [2]. - Tianci Materials: projected increase of 230.63% driven by growth in lithium-ion battery materials [2]. Group 2: Business Improvement and Sustainability - Chuanhua Zhili emphasizes operational improvements and strategic focus on profitable segments, raising questions about the sustainability of these gains amid market competition [1]. - Kangchen Pharmaceutical's profit recovery is linked to reduced impairment provisions from previous acquisitions, which may not indicate a fundamental business turnaround [1]. Group 3: Market Reactions and Investor Behavior - The market's sensitivity to earnings forecasts is driven by a preference for certainty in returns, with high growth projections acting as signals for investment [3]. - There is a tendency among market participants to view year-on-year growth percentages as the sole indicator of performance, which can lead to misinterpretations of a company's true financial health [7]. Group 4: Recommendations for Investors - Investors are advised to analyze the components of earnings forecasts, distinguishing between recurring and non-recurring revenues, and to assess the sustainability of profit growth [7][9]. - Emphasis should be placed on understanding cash flow, competitive advantages, and governance structures rather than solely focusing on accounting figures [11].

Group 1: Financial Performance - The company expects a net profit attributable to shareholders of 3.7 billion to 3.95 billion yuan for 2025, representing a year-on-year growth of 43.41% to 53.10% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 3.87 billion and 4.12 billion yuan, indicating a growth of 51.95% to 61.76% compared to the previous year [1] Group 2: Potash Business - The potash business operated smoothly, achieving a production of 1.0336 million tons and sales of 1.0843 million tons, exceeding annual production and operational targets [1] - The sales price of potash is expected to increase year-on-year due to market supply and demand factors, driving strong revenue and profit growth for this business segment [1] - Cost control measures have proven effective, with the sales cost per ton of potash decreasing year-on-year through continuous optimization of production processes and improved management efficiency [1] Group 3: Lithium Business - The company achieved a lithium carbonate production of 8,808 tons and sales of 8,957 tons, with smooth production and sales coordination following the resumption of operations [2] - The recovery in lithium carbonate prices in the fourth quarter effectively mitigated the impact of earlier production halts, supporting profit growth for the company [2] - The company confirmed an investment income of approximately 2.68 billion yuan, significantly contributing to net profit, primarily due to the performance of its stake in Tibet Julong Copper Co., which benefited from rising copper prices and capacity release [2]

报告期内，公司以经营目标为牵引，进一步发挥内部各专业职能部门协同效应，有效组织生产、保障客 户需求。公司工业品板块（原药及中间体）强化市场研究、把握市场机遇，部分产品量价齐升，带动收 入和毛利增长；公司核心业务—制剂板块深化渠道合力和品牌建设，积极拓展新市场，碧系产品销量稳 定增长，带动收入和毛利的提升。 格隆汇1月12日丨新农股份(002942.SZ)公布，公司预计2025年1月1日—2025年12月31日归属于上市公司 股东的净利润8,700万元–10,500万元，同比增长50.71%-81.89%；扣除非经常性损益后的净利润6,800万 元–8,600万元，同比增长82.90%-131.32%；基本每股收益0.56元/股–0.67元/股。 ...

报告期内，公司以经营目标为牵引，进一步发挥内部各专业职能部门协同效应，有效组织生产、保障客 户需求。公司工业品板块（原药及中间体）强化市场研究、把握市场机遇，部分产品量价齐升，带动收 入和毛利增长；公司核心业务—制剂板块深化渠道合力和品牌建设，积极拓展新市场，碧系产品销量稳 定增长，带动收入和毛利的提升。 格隆汇1月12日丨新农股份(002942.SZ)公布，公司预计2025年1月1日—2025年12月31日归属于上市公司 股东的净利润8,700万元–10,500万元，同比增长50.71%-81.89%；扣除非经常性损益后的净利润6,800万 元–8,600万元，同比增长82.90%-131.32%；基本每股收益0.56元/股–0.67元/股。 ...

格隆汇1月9日丨道通科技(688208.SH)公布，预计2025年年度实现归属于母公司所有者的净利润为9亿元 至9.3亿元，与上年同期相比，将增加25,907万元至28,907万元，同比增长40.42%至45.10%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润为87,000万元至90,000万元，与 上年同期相比，将增加32,923万元至35,923万元，同比增长60.88%至66.43%。 ...

格隆汇1月9日｜华测导航公告，预计2025年度归属于上市公司股东的净利润为6.7亿元-6.9亿元，比上年 同期增长14.84%-18.27%；扣除非经常性损益后的净利润为5.98亿元-6.18亿元，比上年同期增长 18.70%-22.67%。报告期内，公司实现归属于上市公司股东的净利润和归属于上市公司股东的扣除非经 常性损益的净利润稳健增长。 ...

Core Viewpoint - The company expects a significant turnaround in net profit for 2025, projecting a net profit attributable to shareholders of 235 million to 271 million yuan, indicating a year-on-year recovery from losses [1] Group 1: Financial Performance - The company reported a substantial increase in net profit compared to the same period last year, driven by revenue growth from both domestic and international markets [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 212.5 million and 248.5 million yuan, also reflecting a year-on-year recovery [1] - The reduction in financial expenses is attributed to the early redemption of convertible bonds, contributing positively to the overall financial performance [1] Group 2: Revenue Drivers - The increase in net profit is primarily due to enhanced revenue, which was supported by technological innovation, improved utilization rates of formulations and active pharmaceutical ingredients, and rising prices of raw materials [1] - The company anticipates that non-recurring gains and losses will impact net profit by approximately 22.5 million yuan during the reporting period [1]

格隆汇1月8日丨宝丽迪(300905.SZ)公布，预计2025年归属于上市公司股东的净利润14500万元–15200万 元，比上年同期增长27.17%-33.30%，扣除非经常性损益后的净利润14100万元–14800万元，比上年同期 增长36.59%-43.37%。 报告期内，公司持续强化研发创新与市场拓展，推动产品结构优化及市场渗透，实现销量与品质双升， 驱动营业收入保持稳健增长。通过深化成本管控与精益管理，产品毛利率持续改善，带动毛利总额同比 增长。此外，前期实施的股权激励计划进入费用摊销后期，本期股份支付费用较去年同期大幅减少，对 利润增长形成正向支撑。综上，公司经营业绩延续良好增长态势。报告期内，公司非经常性损益对上市 公司归母净利润的影响金额约400万元。 ...

Core Viewpoint - The company expects a net profit attributable to shareholders of 145 million to 152 million yuan for the fiscal year 2025, representing a year-on-year growth of 27.17% to 33.30% [1] Financial Performance - The company has strengthened research and development innovation and market expansion, optimizing product structure to drive both sales and quality improvements [1] - Operating revenue has shown steady growth, while gross profit margin continues to improve, with total gross profit increasing year-on-year [1] - Significant reduction in share-based payment expenses compared to the same period last year has positively impacted profit growth [1]